{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:17:43Z","timestamp":1780319863870,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.ejca.2010.05.010","type":"journal-article","created":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T08:51:44Z","timestamp":1276073504000},"page":"2771-2780","source":"Crossref","is-referenced-by-count":17,"title":["Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines"],"prefix":"10.1016","volume":"46","author":[{"given":"Chandra M.","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Zage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes E.A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.05.010_bib1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.05.010_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/10428190109057981","article-title":"Therapy related leukemias: susceptibility, prevention and treatment","volume":"41","author":"Leone","year":"2001","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.ejca.2010.05.010_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1097-0215(19970328)71:1<9::AID-IJC3>3.0.CO;2-Y","article-title":"Risk of secondary leukemia after treatment with etoposide (VP-16) for langerhans\u2019 cell histiocytosis in Italian and Austrian-German populations","volume":"71","author":"Haupt","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.05.010_bib4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2176\/nmc.37.655","article-title":"Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase IIa","volume":"37","author":"Kuriyama","year":"1997","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.ejca.2010.05.010_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11060-007-9360-0","article-title":"Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity","volume":"84","author":"Uesaka","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2010.05.010_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2010.05.010_bib8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1535-7163.MCT-08-0860","article-title":"Epigenetics in cancer: targeting chromatin modifications","volume":"8","author":"Ellis","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.05.010_bib9","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1158\/1078-0432.CCR-04-1331","article-title":"Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma","volume":"10","author":"Yang","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/gcc.10278","article-title":"Clustering of hypermethylated genes in neuroblastoma","volume":"38","author":"van Noesel","year":"2003","journal-title":"Gene Chromosome Cancer"},{"key":"10.1016\/j.ejca.2010.05.010_bib11","first-page":"6299","article-title":"Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma","volume":"63","author":"Yang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib12","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/0008-5472.CAN-04-0956","article-title":"Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/0008-5472.828.65.3","article-title":"CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas","volume":"65","author":"Abe","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib14","first-page":"3591","article-title":"The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid","volume":"61","author":"Coffey","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bcp.2004.05.010","article-title":"The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells","volume":"68","author":"de Ruijter","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2010.05.010_bib16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.4161\/cc.4.12.2212","article-title":"Histone deacetylase inhibition induces apoptosis in neuroblastoma","volume":"4","author":"Subramanian","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2010.05.010_bib17","first-page":"S91","article-title":"Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases","volume":"83","author":"Gottlicher","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2010.05.010_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pbc.20083","article-title":"Valproic acid treatment of glioblastoma multiforme in a child","volume":"43","author":"Witt","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2010.05.010_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-2008-1043809","article-title":"Valproic acid for the treatment of pediatric malignant glioma","volume":"211","author":"Driever","year":"1999","journal-title":"Klin Pediatr"},{"key":"10.1016\/j.ejca.2010.05.010_bib21","first-page":"97","article-title":"Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha","volume":"20","author":"Cinatl","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2010.05.010_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ijc.22401","article-title":"Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood","volume":"120","author":"Furchert","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.05.010_bib23","first-page":"2643","article-title":"Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture","volume":"33","author":"Biedler","year":"1973","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib24","first-page":"291","article-title":"Biological classification of cell lines derived from human extra-cranial neural tumors","volume":"2","author":"Reynolds","year":"1988","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (\u03b1\/\u03b2) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2010.05.010_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-008-9788-x","article-title":"Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL","volume":"93","author":"Aguilera","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2010.05.010_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/81671","article-title":"Histone deacetylase interacts directly with DNA topoisomerase II","volume":"26","author":"Tsai","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2010.05.010_bib28","first-page":"121","article-title":"The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines","volume":"1","author":"Kurz","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2010.05.010_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.20045","article-title":"Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid","volume":"92","author":"Marchion","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ejca.2010.05.010_bib30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/djm044","article-title":"Histone deacetylase 1 gene expression and sensitization of multi-drug resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide","volume":"99","author":"Keshelava","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.05.010_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2008.11.018","article-title":"Increased topoisomerase II alpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis","volume":"276","author":"Coss","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2010.05.010_bib32","first-page":"1425","article-title":"Topotecan increases topoisomerase IIa levels and sensitivity to treatment with etoposide in schedule-dependent process","volume":"57","author":"Whitacre","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib33","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase II beta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.05.010_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/bj20020791","article-title":"Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites","volume":"368","author":"Lok","year":"2002","journal-title":"Biochem J"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:43:08Z","timestamp":1685626988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":34,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0959804910003825"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.05.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}